Aspaveli is a medication designed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare, life-threatening blood disorder characterized by the destruction of red blood cells, leading to anemia, fatigue, blood clots, and an increased risk of infections. Aspaveli works by inhibiting the complement system, a part of the immune system that plays a central role in the development of PNH by attacking and destroying red blood cells. By targeting and regulating this system, Aspaveli helps to reduce hemolysis (the destruction of red blood cells), alleviate symptoms, and improve the quality of life for patients with PNH. It is typically prescribed by healthcare professionals specialized in the treatment of blood disorders, and its use requires careful monitoring due to the potential for side effects and the need to adjust dosages based on individual patient response.